NHS Logo
Bedfordshire and Luton Joint Formulary
Bedfordshire Hospitals NHS Foundation Trust
Bedfordshire, Luton and Milton Keynes ICB
Formulary items found
Status Description Section
REDTrastuzumab deruxtecan Enhertu®
(100 mg powder for concentrate for solution for infusion) 		Malignant disease and immunosuppression, Other antineoplastic drugs, 08.01.05
Searchiing the National BNF we found these items - Click button under Local to search local formulary or BNF to view on online BNF.
Local BNF Section
Trastuzumab Trastuzumab Deruxtecan [Specialist Drug] Malignant Disease, Antibody Responsive Malignancy, Antineoplastic Drugs Monoclonal Antibodies
Selecting a button in the local column will search the local formulary again for the word on the button. Where the button is in outline no local match at drug name level was found.
Links found
NICE TA1112: Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments (TERMINATED APPRAISAL)
NICE TA704: Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies
NICE TA862: Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments
NICE TA976: Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (TERMINATED APPRAISAL)
NICE TA992: Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy (NOT RECOMMENDED)